Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions.

Stefan GingeleMoritz KochAnna Christina SaparillaGudrun M KörnerJarle von HörstenMarina GingeleTabea SeeligerFranz Felix KonenMartin W HümmertAlexandra NeyaziMartin StangelThomas Skripuletz

Published in: Therapeutic advances in neurological disorders (2021)

Results demonstrate that the switch of IVIg to an equivalent dose of SCIg represents an effective and preferred treatment option for CIDP patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors